Table 1.
The characteristics of the included studies
| First author | Country | Duration | Stage | Cutoffa | Treatment | Design | Follow-up | No of patients | OS,b HR (95% CI) | PFS,b HR (95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|
| Li et al11 | People’s Republic of China | 2002–2009 | I–IV | 2.6 | R-CHOP | R | NR | 438 | 3.11 (1.24–7.81) | 2.76 (1.30–5.85) |
| Watanabe et al14 | Japan | 2003–2009 | I–IV | 4 | R-CHOP | R | 58 | 362 | 2.51 (1.26–5.01) | 2.06 (1.25–3.41) |
| Rambaldi et al24 | Italy | 1984–2012 | III + IV | 2.6 | CT + RT | R | 77 (2–330) | 1,057 | 1.88 (1.32–2.70) | – |
| Koh et al23 | Korea | 2004–2013 | I–IV | 3.04 | R-CHOP | R | 37 (1–131) | 603 | 1.66 (1.18–2.34) | 1.99 (1.47–2.68) |
| Wei et al15 | People’s Republic of China | 2001–2011 | I–IV | 2.6 | CT + S | R | 52 (1–133) | 168 | 1.98 (0.98–3.99) | 2.92 (0.99–8.61) |
| Tadmor et al25 | Serbia | 2004–2012 | I–IV | 2.8 | R-CHOP | R | 34 | 222 | 1.515 (1.00–2.29) | – |
| Markovic et al26 | Israel, Italy | 1993–2010 | I–IV | 2.1 | R-CHOP | R | NR | 1,017 | 1.49 (1.07–2.06) | – |
| Li et al13 | People’s Republic of China | 2001–2011 | I–IV | 3.8 | RT + CT | R | 36 | 244 | 3.95 (2.17–7.20) | 4.07 (2.24–7.39) |
| Ho et al27 | Taiwan | 2001–2010 | I–IV | 2.11 | R-CHOP | R | 53.28 | 148 | 1.53 (0.75–3.11) | 1.40 (0.75–2.59) |
| Jelicic et al28 | Serbia | 2005–2013 | I–IV | 2.8 | R-CHOP, R-CVP | R | NR | 182 | 1.37 (0.711–2.63) | – |
| Belotti et al29 | Italy | 2007–2013 | I–IV | 2.4 | R-CHOP | R | 24 (7.2–61) | 137 | – | 8.00 (0.98–66.67) |
Notes:
a
Result of multivariate analysis based on a reference more than its cutoff value.
b
Multivariate analysis. Stage: Ann Arbor stage.
Abbreviations: OS, overall survival; PFS, progression-free survival; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R, retrospective; NR, not reported; CT, chemotherapy; RT, radio therapy; S, surgery; R-CVP, rituximab, cyclophosphamide, vincristine, and prednisolone; HR, hazard ratio; CI, confidence interval.